Fiche du document
1 avril 2020
- doi: 10.53738/REVMED.2020.16.688.0652
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.688.0652
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32239840
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_11E441D6377E5
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Pitressin Antidiuretic hormone ADH (Hormone)Citer ce document
L. Cuda et al., « La vasopressine chez le patient en état critique [Vasopressin in the critically ill patient] », Serveur académique Lausannois, ID : 10.53738/REVMED.2020.16.688.0652
Métriques
Partage / Export
Résumé
Vasopressin (AVP) is a posterior pituitary hormone initially known for its antidiuretic actions. In this article, we recall the biochemical and pharmacological characteristics of the AVP and its analogues. Currently, its main indication in critical care medicine is vasoplegic shock in view of its vasopressive properties. This strong vasopressive activity is related to the activation of V1 receptors located in the vascular smooth muscle. The scientific evidence of the AVP therapy, and its potential benefits versus norepinephrine in vasoplegic shock, is reviewed in this article. Similarly, we present the other indications of vasopressin in the critical patient, based on recent studies and international guidelines.